Chad M Robins Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 10 hours ago
Chad M Robins has an estimated net worth of at least $66.7 million*, as of yesterday. They own 2.2 million shares of ADPT stock. They have sold 2.8 million shares of ADPT stock since 2021, for an estimated $36.5 million.
Chad M Robins $ADPT SEC Form 4 Insider Trading
Chad M Robins has filed a total of 41 insider trades in $ADPT since 2021. Their most recent trade was a sale of 83,332 shares, made on Apr 06, 2026. Their largest trade was a sale of 329,600 shares, made on Mar 11, 2026. We estimate that they now own 2.2 million shares of $ADPT, worth an estimated $30.1 million.
Insider Trading at $ADPT
There have been a total of 256 insider trades reported at $ADPT since 2021, with 0 shares purchased and 6.9 million shares sold. The most active insider traders in $ADPT stock have been Julie Rubinstein, Harlan S Robins, and Chad M Robins. The most recent trade was a sale of 19,037 shares reported by JULIE RUBINSTEIN (President and COO), made on Apr 27, 2026.
History of Insider Stock Trades by Chad M Robins
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
ADPT
|
Sale | 83,332 | Apr 06, 2026 | April 8, 2026, 7:51 p.m. |
ADPT
|
Sale | 37,263 | Apr 08, 2026 | April 8, 2026, 7:51 p.m. |
ADPT
|
Sale | 140,567 | Mar 11, 2026 | March 13, 2026, 8:45 p.m. |
ADPT
|
Sale | 329,600 | Mar 11, 2026 | March 13, 2026, 8:45 p.m. |
ADPT
|
Sale | 289,024 | Mar 02, 2026 | March 3, 2026, 8:51 p.m. |
ADPT
|
Sale | 2,380 | Mar 03, 2026 | March 3, 2026, 8:51 p.m. |
ADPT
|
Sale | 50,703 | Mar 03, 2026 | March 3, 2026, 8:51 p.m. |
ADPT
|
Sale | 182,891 | Feb 27, 2026 | March 3, 2026, 8:51 p.m. |
ADPT
|
Sale | 124,998 | Feb 02, 2026 | Feb. 4, 2026, 8:37 p.m. |
ADPT
|
Sale | 124,998 | Jan 05, 2026 | Jan. 7, 2026, 9:30 p.m. |
ADPT
|
Sale | 124,998 | Dec 01, 2025 | Dec. 1, 2025, 8:27 p.m. |
ADPT
|
Sale | 35,736 | Nov 26, 2025 | Dec. 1, 2025, 8:27 p.m. |
ADPT
|
Sale | 1,867 | Nov 12, 2025 | Nov. 12, 2025, 8:19 p.m. |
ADPT
|
Sale | 86,161 | Nov 10, 2025 | Nov. 12, 2025, 8:19 p.m. |
ADPT
|
Sale | 1,237 | Nov 11, 2025 | Nov. 12, 2025, 8:19 p.m. |
ADPT
|
Sale | 81,206 | Mar 05, 2025 | March 6, 2025, 8:17 p.m. |
ADPT
|
Sale | 36,145 | Mar 05, 2025 | March 6, 2025, 8:17 p.m. |
ADPT
|
Sale | 102,218 | Mar 06, 2025 | March 6, 2025, 8:17 p.m. |
ADPT
|
Sale | 186,080 | Feb 19, 2025 | Feb. 21, 2025, 8:28 p.m. |
ADPT
|
Sale | 99,107 | Feb 20, 2025 | Feb. 21, 2025, 8:28 p.m. |
ADPT
|
Sale | 158,921 | Feb 14, 2025 | Feb. 18, 2025, 9:21 p.m. |
ADPT
|
Sale | 100,287 | Feb 13, 2025 | Feb. 18, 2025, 9:21 p.m. |
ADPT
|
Sale | 211,160 | Feb 18, 2025 | Feb. 18, 2025, 9:21 p.m. |
ADPT
|
Sale | 5,879 | Mar 05, 2024 | March 6, 2024, 8:40 p.m. |
ADPT
|
Sale | 42,794 | Mar 05, 2024 | March 6, 2024, 8:40 p.m. |
ADPT
|
Sale | 14,815 | Mar 09, 2022 | March 9, 2022, 8 p.m. |
ADPT
|
Sale | 500 | Mar 07, 2022 | March 9, 2022, 8 p.m. |
ADPT
|
Sale | 14,315 | Mar 07, 2022 | March 9, 2022, 8 p.m. |
ADPT
|
Sale | 14,815 | Mar 08, 2022 | March 9, 2022, 8 p.m. |
ADPT
|
Sale | 4,424 | Mar 07, 2022 | March 8, 2022, 10 p.m. |
ADPT
|
Sale | 98 | Sep 10, 2021 | Sept. 9, 2021, 8 p.m. |
ADPT
|
Sale | 11,742 | Sep 08, 2021 | Sept. 9, 2021, 8 p.m. |
ADPT
|
Sale | 2,004 | Sep 08, 2021 | Sept. 9, 2021, 8 p.m. |
ADPT
|
Sale | 24,753 | Sep 09, 2021 | Sept. 9, 2021, 8 p.m. |
ADPT
|
Sale | 4,902 | Sep 10, 2021 | Sept. 9, 2021, 8 p.m. |
ADPT
|
Sale | 1,501 | Jul 12, 2021 | July 13, 2021, 8 p.m. |
ADPT
|
Sale | 19,100 | Jun 15, 2021 | June 16, 2021, 8 p.m. |
ADPT
|
Sale | 900 | Jun 15, 2021 | June 16, 2021, 8 p.m. |
ADPT
|
Sale | 4,745 | Jun 16, 2021 | June 16, 2021, 8 p.m. |
ADPT
|
Sale | 1,000 | Jun 17, 2021 | June 16, 2021, 8 p.m. |
ADPT
|
Sale | 4,255 | Jun 17, 2021 | June 16, 2021, 8 p.m. |
$ADPT Executives and Stock Owners with Insider Trades
-
Julie Rubinstein, President and COO
-
Harlan S Robins, Chief Scientific Officer
-
Chad M Robins, CEO and Chairman
-
R Mark Adams, Chief Operating Officer
-
Chad M Cohen, Chief Financial Officer
-
Francis Lo, Chief People Officer
-
Stacy L Taylor, SVP and General Counsel
-
Kyle Piskel, Chief Financial Officer
-
Sharon Benzeno, Chief Commercial Ofc Imm Med
-
Nitin Sood, Chief Commercial Officer, MRD
-
Kyle Piskel, Principal Accounting Officer
-
Tycho Peterson, Chief Financial Officer
-
Susan Bobulsky, Chief Commercial Officer, MRD
-
Julie Rubinstein, President
-
Jyoti Palaniappan, SVP, Diagnostics, T-Detect
-
Lance Baldo, Chief Medical Officer
-
Sharon Benzeno, Chief Business Development Off
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.